BiotechTube

MAU868 + Placebo

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

BK Virus Nephropathy

Conditions

BK Virus Nephropathy

Trial Timeline

Oct 15, 2018 → Nov 16, 2020

NCT ID
NCT03456999

About MAU868 + Placebo

MAU868 + Placebo is a phase 2 stage product being developed by Novartis for BK Virus Nephropathy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03456999. Target conditions include BK Virus Nephropathy.

What happened to similar drugs?

20 of 20 similar drugs in BK Virus Nephropathy were approved

Approved (20) Terminated (4) Active (0)
✅Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
✅PTV/r/OBV/DSVAbbVieApproved
✅lopinavir/ritonavirAbbVieApproved
✅emtricitabine/tenofovir disoproxil fumarateMerckApproved
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅3-drug anti-HIV therapy + RaltegravirMerckApproved
✅GardasilMerckApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03456999Phase 2Withdrawn

Competing Products

20 competing products in BK Virus Nephropathy

See all competitors
ProductCompanyStageHype Score
Zotatifin + PlaceboeFFECTOR TherapeuticsPhase 1
19
Nanatinostat in combination with valganciclovirViracta TherapeuticsPhase 2
17
AAVLP-HPV + Placebo2A PharmaPhase 1
19
SOF + COPEChugai PharmaceuticalPre-clinical
26
VN-0200 + PlaceboDaiichi SankyoPhase 1
29
VN-0200Daiichi SankyoPhase 2
35
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
43
ASP0113 + PlaceboAstellas PharmaPhase 2
35
ASP0113 + PlaceboAstellas PharmaPhase 3
40
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
32
FK778Astellas PharmaPhase 2
27
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
35
DolutegravirShionogiPhase 3
40
GSK1349572 + efavirenzShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
29
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
40
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29